SyntBioLab Inc.
Empowering Breeders with Effective Antibiotic Alternatives

SyntBioLab stands as a distinguished entity in therapeutics, making notable strides with innovative approaches to combat antibiotic resistance within the poultry and livestock sectors. Harnessing the potential of bacteriophages, the firm provides a sustainable antibiotic alternative, which addresses the growing concerns about pathogenic bacteria like superbugs and their alarming repercussions on human health.

“Our highly concentrated and user-friendly products transform how breeders tackle bacterial infections, leading to faster growth rates, reduced mortality, and improved economic outcomes,” states Rodrigue DUBAR, CEO of SyntBioLab.

The company capitalizes on one of the inherent attributes of bacteriophages as antibacterial viruses that selectively target detrimental bacteria while preserving microbial equilibrium. This approach enables SyntBioLab to mitigate some of the most significant setbacks that breeders had to endure due to the ban on antibiotics as growth enhancers. The issues encompass an unforeseen surge in bacterial infections among livestock, which has resulted in higher mortality rates and significant financial losses. The firm’s use of bacteriophages has enabled it to better align itself with its overarching objective of improving livestock health and helping breeders successfully address their issues.

Compared to conventional antibiotics, SyntBioLab’s technology provides multiple advantages. Notably, bacteriophages exhibit an exceptionally high level of specificity in their ability to target certain bacteria, resulting in minimal disruption to the animal’s microbiome. Being natural biological entities, they also evolve alongside the bacteria and can easily adapt to emerging antibiotic-resistant strains. The use of bacteriophages has yielded impressive outcomes, such as faster growth rates, lower feed consumption, decreased mortality, and slaughter condemnation rates.

Within the archives of SyntBioLab’s success stories, numerous cases serve as clear evidence of the transformative impact of its technology on breeders’ operations and the broader production ecosystem. One such case involves a breeder who had long depended on antibiotics to combat stubborn E. coli infections. However, the perpetual cycle of veterinary prescriptions and the accompanying financial burden propelled the breeder to seek alternative remedies. Upon employing SyntBioLab’s bacteriophage-based products, a remarkable outcome unfurled, marked by a substantial reduction in bacterial infections and the complete eradication of the need for antibiotics.

Besides its novel bacteriophage technology, SyntBioLab owes its success to its experts, who were trained at one of the world’s leading bacteriophage institutions. Their knowledge and hands-on acumen of the core team play a vital role in developing its market-leading solutions. In addition, the firm has sought the expertise of a food chemistry specialist, enabling it to create a resilient formulation that can be seamlessly integrated into animal feed. The specialized know-how effectively elevates SyntBioLab above its contemporaries, assuring the provision of premium, efficacious offerings to its esteemed clientele.

The company’s use of bacteriophages as an effective antibiotic substitute is currently driving a major shift in the livestock industry. Breeders are reaping the rewards of accelerated growth, reduced mortality, and increased economic prosperity due to the technology’s precision and adaptability. SyntBioLab’s commitment to long-term solutions and unrivaled expertise conform to its position as a leader in the therapeutic landscape as it expands its reach to the global market.